

# Resource Summary Report

Generated by [dkNET](#) on Sep 2, 2026

## SV-HUC-1

RRID:CVCL\_3798

Type: Cell Line

---

### Proper Citation

CLS Cat# 305075, RRID:CVCL\_3798

---

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_3798](https://web.expasy.org/cellosaurus/CVCL_3798)

**Proper Citation:** CLS Cat# 305075, RRID:CVCL\_3798

**Description:** Cell line SV-HUC-1 is a Transformed cell line with a species of origin Homo sapiens (Human)

**Sex:** Male

**Defining Citation:** [PMID:1311637](#), [PMID:1767334](#), [PMID:2822239](#), [PMID:2835156](#), [PMID:2841047](#), [PMID:15846775](#), [PMID:27270441](#)

**Comments:** Group: Patented cell line.

**Category:** Transformed cell line

**Organism:** Homo sapiens (Human)

**Name:** SV-HUC-1

**Synonyms:** HUC-1, SV-HUC, SVHUC

**Cross References:** BTO:BTO\_0003908, CLO:CLO\_0009177, ATCC:CRL-9520, BCRC:60358, BioSample:SAMN03471218, CCRID:3101HUMTCHu169, CLS:305075, Cosmic:687554, KCB:KCB 2012112YJ, Wikidata:Q54970934

**ID:** CVCL\_3798

**Vendor:** CLS

**Catalog Number:** 305075

**Record Creation Time:** 20220923T071614+0000

**Record Last Update:** 20260830T000611+0000

---

## Ratings and Alerts

No rating or validation information has been found for SV-HUC-1.

No alerts have been found for SV-HUC-1.

---

## Data and Source Information

**Source:** [Cellosaurus](#)

---

## Usage and Citation Metrics

We found 469 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [dkNET](#) .

Wu J, et al. (2026) O-GlcNAcylated TAP1 Impairs Antigen Presentation and Promotes Immune Evasion in Bladder Cancer. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(37), e19955.

Ying X, et al. (2026) m5C-Modified tRF3b-CysGCA-23 Suppresses Bladder Cancer Malignancy by Repressing H3K18 Lactylation via Stabilizing RBM4. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(26), e22294.

Jin Z, et al. (2026) HOXB4 Promotes Bladder Cancer Progression in Part Through Transcriptional Activation of Smoothed. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, 40(1), e71388.

Qin X, et al. (2026) A 'two-in-one' tumor-specific-hydrogel-assisted strategy for intravesical chemotherapy and protection of normal tissues. *Journal of nanobiotechnology*, 24(1).

Wang JS, et al. (2026) HSPB6: A Potential Prognostic Biomarker, Inhibiting the Epithelial-Mesenchymal Transition (EMT) Process Through the PI3K/Akt Signaling Pathway Based on the Machine Learning and Experimental Validation. *Human mutation*, 2026, 4843618.

Iskender B, et al. (2026) Reprogramming-driven Proteomic Shifts Mirror Bladder Cancer Progression and Reveal Biomarker Candidates Across Disease Grades. *Cancer genomics & proteomics*, 23(4), 777.

Fu H, et al. (2026) A smart gene circuit for precise regulation of tumor cell behavior. *Synthetic and systems biotechnology*, 11, 237.

Shi Y, et al. (2026) piR-43452 suppresses bladder cancer progression and enhances gemcitabine sensitivity via GTSE1/PIWIL4-mediated LRP1 mRNA destabilization. *Translational oncology*, 63, 102626.

Yu K, et al. (2026) Lactylation enhances YTHDF3 stability to promote cisplatin resistance via m6A-dependent KDM6B decay in bladder cancer. *Cancer letters*, 642, 218282.

Shangguan W, et al. (2026) FomA-Containing Outer Membrane Vesicles of *Fusobacterium Nucleatum* Facilitate Bladder Cancer Lymphatic Metastasis via IL-6-Dependent M2b Macrophage Polarization. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(23), e23256.

Barlak BSR, et al. (2026) Proteomic Signatures of Cellular Reprogramming in Bladder Cancer: Insights into the Acquisition of Cancer Stem-like States and Phenotypic Plasticity. *Cancer genomics & proteomics*, 23(2), 300.

Zhang J, et al. (2026) Intravesical instillation of pirfenidone/polydopamine nanoparticles for managing neurogenic bladder post-spinal cord injury by alleviating bladder inflammation and fibrosis. *Journal of nanobiotechnology*, 24(1), 154.

Iskender B, et al. (2026) Conjoining cell reprogramming and mass spectrometry to identify the proteomic variations in the reprogrammed bladder cancer cells: finding cues of normalisation. *BMC cancer*, 26(1).

Chen C, et al. (2025) TERC Stimulates Fatty Acid Metabolism to Promote Bladder Cancer Progression. *Cancer research*, 85(19), 3689.

Wang JM, et al. (2025) KIF26B promotes bladder cancer progression via activating Wnt/??-catenin signaling in a TRAF2-dependent pathway. *Cell reports*, 44(5), 115595.

Wang X, et al. (2025) PIN1 Prolyl Isomerase Promotes Initiation and Progression of Bladder Cancer through the SREBP2-Mediated Cholesterol Biosynthesis Pathway. *Cancer discovery*, 15(3), 633.

Yu Y, et al. (2025) A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer. *Cancer research*, 85(12), 2288.

Li Y, et al. (2025) Comprehensive pan-cancer single-cell analysis reveals glycolysis-related signatures as predictive biomarkers for immunotherapy response and their role in bladder cancer. *International immunopharmacology*, 152, 114381.

Hosking MP, et al. (2025) Preferential tumor targeting of HER2 by iPSC-derived CAR T cells engineered to overcome multiple barriers to solid tumor efficacy. *Cell stem cell*, 32(7), 1087.

Guo X, et al. (2025) tRF-21LeuTAA Promotes Oxidative Stress by Altering Glutathione Metabolic Enzymes to Support Prostate Cancer Progression. *Cancer research*, 85(23), 4787.